Juan Manuel Domínguez received his PhD in Biochemistry from the Complutense University of Madrid, where he was awarded the Extraordinary Undergraduate and Doctorate Prizes in 1987 and 1992.

After his academic period, in which he specialised in protein chemistry and enzymology, he accumulated nearly thirty years’ experience in research in the pharmaceutical industry, focusing his activity primarily on the initial phases of the drug discovery process.

In 1992, he joined the Biochemistry Department of the multinational pharmaceutical company Glaxo as a researcher, where he worked for several years on the identification of new anti-infective agents and research into their mechanism of action.

In 2001, he became head of the Assay Development Department at GlaxoSmithKline, where he focused on the biochemical characterisation of new therapeutic targets, the development of biological assays in high-throughput format and the execution of the relevant studies to understand the mechanism of action of the chemical compounds selected in these assays.

During these years, Dr. Domínguez led international projects involving experts in various scientific disciplines and worked in several laboratories outside Spain. In 2008 he joined PharmaMar group companies, first at Noscira where he headed the Drug Identification Department and since 2013 at PharmaMar where he headed the Screening Department.

He is the author of more than 40 publications and book chapters as well as several patents and oral presentations. A member of the editorial board of the Journal of Biomolecular Screening from 2012 to 2017, he is a frequent reviewer of papers for numerous publications in the sector such as SLAS Discovery, Biochemical Pharmacology and Theranostics. He also collaborates as a lecturer in several postgraduate master’s degrees at the Complutense University of Madrid and the Autonomous University of Madrid.